TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
EQL Pharma AB ( (SE:EQL) ) has shared an update.
EQL Pharma AB has announced that its key product, Mellozzan® (melatonin), has been approved for sale in Turkey by the Turkish Medicines Agency. The product will be manufactured and marketed locally by EQL’s partner, Abdi Ibrahim, with sales expected to begin in the first half of 2026. This approval marks a significant step for EQL Pharma’s expansion into new markets, potentially enhancing its market presence and providing new revenue streams. Additionally, there are plans to expand Mellozzan® with an oral solution in Turkey by 2027, and applications have been submitted for approval in Kazakhstan.
More about EQL Pharma AB
EQL Pharma AB is a company that specializes in developing and selling generic drugs, focusing on niche generics with limited competition. The company operates primarily in the Nordic and European markets, with a significant pipeline of products. EQL Pharma collaborates with leading contract manufacturers and pharmaceutical companies in the EU and Asia, and is listed on the Nasdaq Stockholm stock market.
Average Trading Volume: 31,146
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.55B
See more data about EQL stock on TipRanks’ Stock Analysis page.